SCHEMBL2811213

SCHEMBL2811213

O=C(O)c1c[nH]c2c(C(=O)O)cccc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
KDM4E B2RXH2 5/20 0.55
KEAP1 Q14145 1/20 0.53
BRPF1 P55201 1/20 0.53
CSNK2A2 P19784 2/20 0.53
CSNK2B P67870 2/20 0.53
CSNK2A1 P68400 2/20 0.53
ALDH1A1 P00352 3/20 0.53
HPGD P15428 1/20 0.53
DNA2 P51530 1/20 0.51
CASP6 P55212 1/20 0.51
CTDSP1 Q9GZU7 1/20 0.51
NR4A2 P43354 3/20 0.50
NR4A1 P22736 1/20 0.50
NR4A3 Q92570 1/20 0.50
PBRM1 Q86U86 1/20 0.50
GFER P55789 2/20 0.49
MAPT P10636 1/20 0.49
PIM1 P11309 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29415445 1.00 HTT (0.59) HTTSMN1; SMN2KDM4EKEAP1BRPF1
SCHEMBL27566973 0.91 PIM1 (0.55) HTTSMN1; SMN2KDM4EKEAP1BRPF1
SCHEMBL18589537 0.89 CSNK2A2 (0.69) HTTSMN1; SMN2KDM4EKEAP1CSNK2A2
SCHEMBL10086124 0.85 HTT (0.54) HTTSMN1; SMN2KDM4EKEAP1BRPF1
SCHEMBL27491481 0.85 HTT (0.54) HTTSMN1; SMN2KDM4EKEAP1BRPF1
SCHEMBL3978031 0.82 BRPF1 (0.77) HTTSMN1; SMN2KDM4EBRPF1CSNK2A2
SCHEMBL2036977 0.82 NR4A2 (0.69) HTTKDM4EBRPF1CSNK2A2CSNK2B
SCHEMBL2035484 0.82 GPR84 (0.53) KDM4EBRPF1CSNK2A2CSNK2BCSNK2A1
SCHEMBL3762044 0.82 KDM4E (0.50) HTTSMN1; SMN2KDM4EBRPF1CSNK2A2
SCHEMBL31542356 0.82 NR4A2 (0.69) HTTKDM4EBRPF1CSNK2A2CSNK2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8968711-B2 Cosmetic or dermatological composition comprising a polymer bearing junction groups, and cosmetic treatment process L'OREAL (FR) 2015-03-03 US claimed
US-20100272660-A1 COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT L'OREAL (FR) 2010-10-28 US claimed
US-20100239509-A1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS L'OREAL (FR) 2010-09-23 US claimed
US-11559474-B2 Hair lightening compositions and methods of use L'OREAL (FR) 2023-01-24 US disclosed
US-8968711-B2 Cosmetic or dermatological composition comprising a polymer bearing junction groups, and cosmetic treatment process L'OREAL (FR) 2015-03-03 US disclosed
US-20100272660-A1 COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT L'OREAL (FR) 2010-10-28 US disclosed
US-20100239509-A1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS L'OREAL (FR) 2010-09-23 US disclosed
US-20090028807-A1 COMPOSITION COMPRISING A POLYCONDENSATE, METHOD OF TREATMENT, POLYCONDENSATE, AND METHOD OF PREPARATION L'OREAL (FR) 2009-01-29 US disclosed
US-4093622-A Pyridine esters of cyclopropane-carboxylic acid ZOECON CORPORATION (US) 1978-06-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239509-A1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS CUTA, SUCLG1, KRT18 HTT 2106/4885SMN1; SMN2 4595/4885KDM4E 2504/4885
US-20090028807-A1 COMPOSITION COMPRISING A POLYCONDENSATE, METHOD OF TREATMENT, POLYCONDENSATE, AND METHOD OF PREPARATION CUTA, SYMPK, TPRKB HTT 443/4885SMN1; SMN2 2672/4885KDM4E 1615/4885
US-20100272660-A1 COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT ACMSD, CUTA, PCCA HTT 488/4885SMN1; SMN2 3730/4885KDM4E 1109/4885
US-11559474-B2 Hair lightening compositions and methods of use TYR, ALAD, CYBA HTT 478/4885SMN1; SMN2 4423/4885KDM4E 2585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.